EUCTR2015-005276-14-DK进行中（未招募）1 期
Prolonging the response by low-dose Rituximab maintenance therapy in immune thrombocytopenia: a randomized placebo-controlled trial- the PROLONG trial. - PROLONG-trial
Sykehuset Østfold HF0 个研究点目标入组 130 人开始时间: 2016年10月19日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 130
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •First randomization (Induction phase)
- •1. Male or female aged =18 years.
- •2. Diagnosis of primary ITP of less than one-year duration and having a platelet count of = 30 x109/L measured within 4 weeks prior to inclusion with failure to achieve response or relapse after one or more cycles of dexamethasone (40 mg daily for 4 days) or after at least 3 weeks under any other steroid (prednisone or prednisolone). Platelet count between 31 to 50 x109/L is accepted if higher platelet count is required due to concomitant antiplatelet therapy or bleeding.
- •3. Scheduled intravenous treatment of rituximab.
- •4. Rituximab infusion will be more than 2 weeks after the first injection of an anti-COVID-19 vaccine.
- •5. Signed and dated written informed consent.
- •6. Females of child-bearing potential accepting to follow effective contraceptive methods for at least 12 months following the last administration of rituximab or placebo.
- •Second randomization (maintenance phase)
- •7. Completion of the induction phase (phase 1) of the study.
- •8. Sustained response at the end of phase 1.
- •9. Randomization within:
- •a. 4 weeks after the completion of phase 1, i.e. between week 24 and 28 for a patient who can’t be vaccinated or is already vaccinated against COVID-19 or,
- •b. 16 weeks after the completion of phase 1 if needed to allow the patient to receive anti-COVID-19 vaccine (see Section 10.4.5.2. for vaccination recommendations).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 75
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 55
排除标准
- •First randomization (Induction phase)
- •1. Previous treatment for ITP with: rituximab, other immune suppressants (including mycophenolate mofetil, azathioprin, cyclosporine), dapsone, danazol, thrombopoietin receptor agonist, chemotherapy or splenectomy.
- •2. Anti-COVID-19 unvaccinated patient with at least one of the following characteristics:
- •a. =65 years old
- •c. Diagnosed Arterial hypertension
- •d. Diagnosed Diabetes mellitus
- •e. Known Kidney disease
- •f. Known Lung disease
- •3. Pregnancy or lactation.
- •4. Known active gastro-duodenal ulcer.
- •5. Secondary ITP: ITP associated with lymphoma, chronic lymphocytic leukemia, drug induced or ITP secondary to autoimmune disorders such as Systemic Lupus Erythematosis, Rheumatoid arthritis or Antiphospholipid syndrome, common variable immune deficiency, human immunodeficiency virus, hepatitis C or thrombocytopenia associated with myeloid dysplasia.
- •6. Concomitant autoimmune hemolytic anemia.
- •7. History of any major cardiovascular event within the 6 months prior to randomization, including but not limited to: myocardial infarction, unstable angina, cerebrovascular accident, or New York Heart Association Class III or IV heart failure.
- •8. Active hepatitis B virus or patients with positive HBsAG or HBcAB.
- •9. Patients with active severe infection, including systemic mycotic infections or a history of recurring or chronic infections or with underlying conditions which may further predispose patients to serious infection.
- •10. Known allergy and/or sensitivity or contraindication to rituximab or dexamethasone or any of the ingredients.
- •11. Patients in a severely immune compromised state.
- •12. Known contraindication to a treatment with any proton-pump inhibitor.
- •13. Active malignancy or history of malignant disease during the last 2 years
- •14. Patients with history of poor compliance or history of alcohol/drug abuse or excessive alcohol beverage consumption that would interfere with the ability to comply with the study protocol, or current or past psychiatric disease that might interfere with the ability to comply with the study protocol or give informed consent.
- •Second randomization (maintenance phase)
- •1. Severe allergic reaction or serum sickness due to rituximab in phase 1 of the study.
- •2. Pregnancy.
- •3. Treatment with rescue medication after week 18.
- •4. Patients refusing to continue in the study (withdrawal of consent).
- •5. Splenectomy performed for any cause.
研究者
相似试验
已完成
3 期
The PROLONG Trial - Rituximab Maintenance Therapy in ITPPurpura, Thrombocytopenic, IdiopathicNCT03010202Ostfold Hospital Trust136
尚未招募
2 期
Cure rate of childhood B cell lymphoma with rituximab and reduced strength of chemotherapyCTRI/2017/09/009650Cancer Institute adyar
尚未招募
2 期
Rituximab maintenance therapy in nephrotic syndromeCTRI/2022/02/040186Dr Arpita Raychaudhury
Unknown
3 期
Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell LymphomaCD20+ Aggressive Lymphoma, Mantle Cell LymphomaNCT01933711University Hospital Heidelberg328
进行中（未招募）
1 期
Very low doses of Rituximab for autoimmune diseases, for which rituximab is not approved for - a Pilot TrialAutoimmune-haemolytic AnemiaAntiphospholipid SyndromeImmune-mediated ThrombocytopeniaMedDRA version: 20.0Level: LLTClassification code 10003825Term: Autoimmune hemolytic anemiaSystem Organ Class: 100000154058MedDRA version: 20.0Level: LLTClassification code 10023095Term: ITPSystem Organ Class: 100000157088MedDRA version: 20.0Level: PTClassification code 10002817Term: Antiphospholipid syndromeSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2016-002478-11-ATMedical University of Vienna, Department of Internal medicine I48